Effective Post-Exposure Treatment of Ebola Infection (2007)
Heinz Feldmann, Steven M. Jones, Joan B. Geisbert, Ute Ströher, Allen Grolla, ...
Ebola viruses are highly lethal human pathogens that have received considerable attention in recent years due to an increasing re-emergence in Central Africa and a potential for use as a biological...
Neutralizing Antibody Fails to Impact the Course of Ebola Virus Infection in Monkeys (2007)
Wendelien B. Oswald, Thomas W. Geisbert, Kelly J. Davis, Joan B. Geisbert, Nancy J. Sullivan, Peter B. Jahrling, ...
Prophylaxis with high doses of neutralizing antibody typically offers protection against challenge with viruses producing acute infections. In this study, we have investigated the ability of the...
Nancy J. Sullivan, Thomas W. Geisbert, Joan B. Geisbert, Devon J. Shedlock, Ling Xu, Laurie Lamoreaux, ...
A simplified Ebola vaccine that consists of a modified GP protein (which is well-tolerated by human cells even at high concentrations) in a replication-defective adenoviral vector protects macaques.
Nancy J. Sullivan, Thomas W. Geisbert, Joan B. Geisbert, Devon J. Shedlock, Ling Xu, Laurie Lamoreaux, ...
BackgroundEbola virus causes a hemorrhagic fever syndrome that is associated with high mortality in humans. In the absence of effective therapies for Ebola virus infection, the development of a...
Development of a New Vaccine for the Prevention of Lassa Fever (2005)
Thomas W. Geisbert, Steven Jones, Elizabeth A. Fritz, Amy C. Shurtleff, Joan B. Geisbert, Ryan Liebscher, ...
A replication-competent vaccine based on attenuated recombinant vesicular stomatitis virus vector protects non- human primates.
Development of a New Vaccine for the Prevention of Lassa Fever (2005)
Thomas W. Geisbert, Steven Jones, Elizabeth A. Fritz, Amy C. Shurtleff, Joan B. Geisbert, Ryan Liebscher, ...
Background Recent importation of Lassa fever into Germany, the Netherlands, the United Kingdom, and the United States by travelers on commercial airlines from Africa underscores the public health...
Mellquist-Riemenschneider, Jenny L., Garrison, Aura R., Geisbert, Joan B., Saikh, Kamal U., Heidebrink, Kelli D.
The filoviruses Ebola virus (EBOV) and Marburg virus (MARV) cause severe hemorrhagic fever in humans for which no vaccines are available. Previously, a priming dose of a DNA vaccine expressing the...
Geisbert, Thomas W., Hensley, Lisa E., Jahrling, Peter B., Larsen, Tom, Geisbert, Joan B.
Infection with the Ebola virus induces overexpression of the procoagulant tissue factor in primate monocytes and macrophages, suggesting that inhibition of the tissue-factor pathway could ameliorate...
Jones, Steven M., Feldmann, Heinz, Stroher, Ute, Geisbert, Joan B., Fernando, Lisa, Grolla, Allen, ...
Vaccines and therapies are urgently needed to address public health needs stemming from emerging pathogens and biological threat agents such as the filoviruses Ebola virus (EBOV) and Marburg virus...
Daddario-DiCaprio, Kathleen M., Geisbert, Thomas W., Stroher, Ute, Geisbert, Joan B., Grolla, Allen, Fritz, Elizabeth A., ...
Effective countermeasures are urgently needed to prevent and treat infections caused by highly pathogenic and biological threat agents such as Marburg virus (MARV). We aimed to test the efficacy of a...
Development of a New Vaccine for the Prevention of Lassa Fever
Geisbert, Thomas W, Jones, Steven, Fritz, Elizabeth A, Shurtleff, Amy C, Geisbert, Joan B, Liebscher, Ryan, ...
A replication-competent vaccine based on attenuated recombinant vesicular stomatitis virus vector protects non- human primates.
Sullivan, Nancy J, Geisbert, Thomas W, Geisbert, Joan B, Shedlock, Devon J, Xu, Ling, Lamoreaux, Laurie, ...
A simplified Ebola vaccine that consists of a modified GP protein (which is well-tolerated by human cells even at high concentrations) in a replication-defective adenoviral vector protects macaques.
Development of a New Vaccine for the Prevention of Lassa Fever
Geisbert, Thomas W, Jones, Steven, Fritz, Elizabeth A, Shurtleff, Amy C, Geisbert, Joan B, Liebscher, Ryan, ...
A replication-competent vaccine based on attenuated recombinant vesicular stomatitis virus vector protects non- human primates.
Sullivan, Nancy J, Geisbert, Thomas W, Geisbert, Joan B, Shedlock, Devon J, Xu, Ling, Lamoreaux, Laurie, ...
A simplified Ebola vaccine that consists of a modified GP protein (which is well-tolerated by human cells even at high concentrations) in a replication-defective adenoviral vector protects macaques.
Neutralizing Antibody Fails to Impact the Course of Ebola Virus Infection in Monkeys
Oswald, Wendelien B, Geisbert, Thomas W, Davis, Kelly J, Geisbert, Joan B, Sullivan, Nancy J, Jahrling, Peter B, ...
Prophylaxis with high doses of neutralizing antibody typically offers protection against challenge with viruses producing acute infections. In this study, we have investigated the ability of the...
Effective Post-Exposure Treatment of Ebola Infection
Feldmann, Heinz, Jones, Steven M, Daddario-DiCaprio, Kathleen M, Geisbert, Joan B, Ströher, Ute, Grolla, Allen, ...
Ebola viruses are highly lethal human pathogens that have received considerable attention in recent years due to an increasing re-emergence in Central Africa and a potential for use as a biological...
Cross-Protection against Marburg Virus Strains by Using a Live, Attenuated Recombinant Vaccine
Daddario-DiCaprio, Kathleen M., Geisbert, Thomas W., Geisbert, Joan B., Ströher, Ute, Hensley, Lisa E., Grolla, Allen, ...
Marburg virus (MARV) has been associated with sporadic episodes of hemorrhagic fever, including a recent highly publicized outbreak in Angola that produced severe disease and significant mortality in...
Geisbert, Thomas W., Hensley, Lisa E., Larsen, Tom, Young, Howard A., Reed, Douglas S., Geisbert, Joan B., ...
Ebola virus (EBOV) infection causes a severe and fatal hemorrhagic disease that in many ways appears to be similar in humans and nonhuman primates; however, little is known about the development of...
Neumann, Gabriele, Geisbert, Thomas W., Ebihara, Hideki, Geisbert, Joan B., Daddario-DiCaprio, Kathleen M., Feldmann, Heinz, ...
Enveloped viruses often require cleavage of a surface glycoprotein by a cellular endoprotease such as furin for infectivity and virulence. Previously, we showed that Ebola virus glycoprotein does not...
Geisbert, Thomas W., Daddario-DiCaprio, Kathleen M., Williams, Kinola J. N., Geisbert, Joan B., Leung, Anders, Feldmann, Friederike, ...
Recombinant vesicular stomatitis virus (VSV) vectors expressing homologous filoviral glycoproteins can completely protect rhesus monkeys against Marburg virus when administered after exposure and can...